Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  1 
Version 1, March 6 , 2010  TREATMENT OF MUCOCUTANEOUS LEISHMANIASIS  
WITH MILTEFOSINE  
 
Protocol No.  PLB -MIL T-201 
 
 
Principal Investigator:   Jonathan D. Berman, M.D., Ph.D.  
     Sr. Vice President for Clinical Affairs  
Fast-Track Drugs and Biologics, LLC  
5 Paramus Court  
North Potomac  MD 20878  
301-922-2097  
jberman@fasttrackresearch.com  
 
Associate Investigator:   Janet H. Ransom, Ph.D.  
     Fast-Track Drugs and Biologics, LLC  
5 Paramus Court  
North Potomac, Maryland 20878  
Tel: (301) 762 -5787  
     jransom@fasttrackresearch.com  
 
Consultant :    Jaime Soto, M.D.  
     Prodderma  
     Calle Ayacucho 416, Of. 104  
     Santa Cruz, Bolivia  
     (011) 59 13 402 4000  
     jaime.soto@prodderma.com     
 
Sponsor:     Paladin Labs Inc. (USA)  
 
Sponsor’s Contact:    Robert K. Vinson, Ph.D.  
Paladin Labs Inc.  
100 Blvd. Alexis Nihon, Suite 600  
St-Laurent, Québec H4M 2P2  
Tel: (514) 669 -5323     
rvinson@paladinlabs.com  
  
Data Management Center:   Fast-Track Drugs and Biologics, LLC  
5 Paramus Court  
North Potomac, Maryland 20878  
Tel: (301) 762 -5787  
Fax: (301) 762 -5730 
     kkell @fasttrackresearch.com  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  2 
Version 1, March 6 , 2010   
TABLE OF CONTENTS  
 
1 LIST OF ABBREVIATIONS AND DEFINITIONS  ................................ .............................  5 
2 STUDY SCHEDULE  ................................ ................................ ................................ .............  6 
3 ABSTRACT  ................................ ................................ ................................ ............................  7 
4 INTRODUCTION AND RATIONALE  ................................ ................................ ...............  10 
4.1 Mucocutaneous Leishmaniasis (Mu rray et al., 2005)  ................................ ...................  10 
4.1.1  Clinical Spectrum ................................ ................................ ................................ .. 10 
4.1.2  Diagnosis ................................ ................................ ................................ ...............  10 
4.1.3  Treatment with Classical Agents  ................................ ................................ ..........  10 
4.2 Miltefosine  ................................ ................................ ................................ ....................  11 
4.2.1  Dosage and Administration ................................ ................................ ...................  11 
4.2.2  Contraindications  ................................ ................................ ................................ .. 11 
4.2.3  Warnings and Precautions ................................ ................................ .....................  12 
4.2.4  Adverse Reactions  ................................ ................................ ................................  12 
4.2.5  Drug Interactions  ................................ ................................ ................................ .. 12 
4.2.6  Use in Specific Populations  ................................ ................................ ..................  12 
4.2.7  Clinical and Non -clinical Pharmacology  ................................ ..............................  13 
4.2.8  Clinical Studies in Mucocutaneous Leishmaniasis  ................................ ...............  14 
4.2.9  References  ................................ ................................ ................................ .............  20 
5 STUDY OBJECTIVES  ................................ ................................ ................................ .........  21 
5.1 Primary  ................................ ................................ ................................ ..........................  21 
5.2 Secondary  ................................ ................................ ................................ ......................  21 
6 STUDY DESIGN ................................ ................................ ................................ ..................  21 
7 STUDY SUBJECTS  ................................ ................................ ................................ .............  21 
7.1.1  Estimated Number of Subjects ................................ ................................ ..............  21 
7.1.2  Inclusion Criteria  ................................ ................................ ................................ .. 21 
7.1.3  Exclusion Criteria  ................................ ................................ ................................ . 21 
8 INVESTIGATIO NAL PRODUCT  ................................ ................................ .......................  22 
8.1 Description  ................................ ................................ ................................ ....................  22 
8.2 Labeling  ................................ ................................ ................................ ........................  22 
8.2.1  Storage  ................................ ................................ ................................ ..................  23 
8.2.2  Drug Accountability ................................ ................................ ..............................  23 
8.3 Start of Treatment  ................................ ................................ ................................ .........  23 
8.4 Administration of Investigational Product (Miltefosine)  ................................ ..............  23 
8.5 Allocation of Study Treatment to Subject and Compliance  ................................ .........  24 
8.6 Treatment Modifications and Study Discontinuation  ................................ ...................  24 
8.7 Concomitant Therapy ................................ ................................ ................................ .... 24 
8.8 Rescue Treatment ................................ ................................ ................................ ..........  24 
9 STUDY PROCEDURES  ................................ ................................ ................................ ...... 25 
9.1 Subject Recruitment  ................................ ................................ ................................ ...... 26 
9.2 Screening Procedures  ................................ ................................ ................................ .... 26 
9.3 Assessment During Miltefosine Treatment  ................................ ................................ .. 27 
9.3.1  Study Day 1 ................................ ................................ ................................ ...........  27 
9.3.2  Study  Days 7 and 14  ................................ ................................ .............................  27 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  3 
Version 1, March 6 , 2010  9.3.3  Study Day 28 ................................ ................................ ................................ .........  27 
9.3.4  Study Week 6  ................................ ................................ ................................ ........  28 
9.3.5 Study Month 3 ................................ ................................ ................................ ....... 28 
9.3.6  Study Month 7 ................................ ................................ ................................ ....... 28 
9.3.7  Study Month 13 ................................ ................................ ................................ ..... 28 
10 EFFICACY  ................................ ................................ ................................ .......................  30 
10.1 Efficacy Assessments of CL Subjects ................................ ................................ ...........  30 
10.1.1  Assessment Methods  ................................ ................................ .............................  30 
10.1.2  Definitions of Clinical Response  ................................ ................................ ..........  30 
10.1.3  Definition of Lesion Responses  ................................ ................................ ............  30 
10.1.4  Definitio n of Subject Responses  ................................ ................................ ...........  31 
10.2 Efficacy Assessment of ML Subjects  ................................ ................................ ...........  31 
10.2.1  Assessment Methods  ................................ ................................ .............................  31 
10.2.2  Clinical Parameter and Definition of Clinical Responses ................................ ..... 31 
10.2.3  Definition of Subject Responses  ................................ ................................ ...........  31 
10.3 Withdrawal from Protocol for Lack of Efficacy  ................................ ...........................  32 
11 SAFETY/ADVERSE EVENTS ................................ ................................ ........................  33 
11.1 Assessment Methods  ................................ ................................ ................................ ..... 33 
11.1.1  Symptoms  ................................ ................................ ................................ .............  33 
11.1.2  Signs  ................................ ................................ ................................ ......................  33 
11.1.3  Laboratory Assessments  ................................ ................................ .......................  33 
11.1.4  Pregnancy Test  ................................ ................................ ................................ ...... 33 
11.1.5  Electrocardiogram (ECG)  ................................ ................................ .....................  33 
11.2 AE Definition  ................................ ................................ ................................ ................  34 
11.3 Severity Definitions  ................................ ................................ ................................ ...... 34 
11.4 Assessment of Causality  ................................ ................................ ...............................  35 
11.5 AE Actions and Outcomes  ................................ ................................ ............................  35 
11.6 Monitoring and Reporting of Adverse Events  ................................ ..............................  35 
11.7 Serious Adverse Event (SAE)  ................................ ................................ .......................  36 
11.8 SAE Reporting Requirements  ................................ ................................ .......................  36 
12 ANALYTICAL PLAN  ................................ ................................ ................................ ..... 37 
12.1 Sample Size  ................................ ................................ ................................ ...................  37 
12.2 Analytical Populations  ................................ ................................ ................................ .. 37 
12.3 General Analytical Procedures  ................................ ................................ .....................  37 
12.4 Analysis of Baseline Data  ................................ ................................ .............................  37 
12.5 Analysis of Treatment Compliance Data  ................................ ................................ ...... 37 
12.6 Analysis of Efficacy Outcomes of CL Subjects  ................................ ...........................  37 
12.6.1  Lesion Area Measurements ................................ ................................ ...................  37 
12.6.2  Lesion and Subject Cure Rate  ................................ ................................ ...............  37 
12.6.3  Handling of Missing Data  ................................ ................................ .....................  38 
12.7 Analysis of Efficacy Outcomes of ML Subjects ................................ ...........................  38 
12.7.1 Lesion assessments  ................................ ................................ ...............................  38 
12.7.2  Subject Cure Rate  ................................ ................................ ................................ . 38 
12.7.3  Handling of Missing Data  ................................ ................................ .....................  38 
12.8 Analysis of Safety Data  ................................ ................................ ................................  38 
13 ADMINISTRATIVE AND REGULATORY STANDARDS ................................ ..........  39 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  4 
Version 1, March 6 , 2010  13.1 Ethical Review of Pr otocol  ................................ ................................ ...........................  39 
13.2 Informed Consent ................................ ................................ ................................ ..........  39 
13.3 Responsibility for Subject Care  ................................ ................................ ....................  39 
13.4 Treatment Cost  ................................ ................................ ................................ ..............  39 
13.5 Protocol Exemption Committee  ................................ ................................ ....................  39 
14 STUDY DOCUMENTATION/DATA MANAGEMENT  ................................ ...............  39 
14.1 Subject Identification (ID) Code  ................................ ................................ ...................  39 
14.2 Data Collection and Monitoring  ................................ ................................ ...................  39 
14.3 Data Editing and Control  ................................ ................................ ..............................  40 
14.4 Data Analysis  ................................ ................................ ................................ ................  40 
14.5 Publication  ................................ ................................ ................................ ....................  40 
14.6 Subject Confidentiality  ................................ ................................ ................................ . 41 
15 ROLES AND RESPONSIBILITIES OF STUDY PERSONNEL ................................ .... 41 
15.1 Principal Investigator  ................................ ................................ ................................ .... 41 
15.2 Associate Investigator  ................................ ................................ ................................ ... 41 
15.3 Treating Physicians  ................................ ................................ ................................ ....... 41 
15.4 Data Management Center  ................................ ................................ .............................  42 
16 STATEMENT OF AGREEMENT  ................................ ................................ ...................  42 
17 SIGNATURES  ................................ ................................ ................................ ..................  42 
 
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  5 
Version 1, March 6 , 2010  1 LIST OF ABBREVIATION S AND DEFINITIONS  
 
AE adverse event  
ALT   alanine  transaminase  
BUN  blood urea nitrogen  
CL cutaneous leishmaniasis  
CRF  case report form  
CTC  Common  Terminology Criteria  
DCL  diffuse cutaneous leishmaniasis  
DNA  deoxyribonucleic acid  
ENT  ear-nose-throat  
ECG  elect rocardiogram  
FDA  food and drug administration  
IND investigational drug application  
IRB institutional review board  
mITT  Modified Intention -to-treat 
ML mucosal leishmaniasis  
MSS  mucosal severity score  
PCR  polymerase chain reaction  
PE physical examination  
PI Principal I nvestigator  
SAE  serious adverse event  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  6 
Version 1, March 6 , 2010  2 STUDY SCHEDULE  
 
Time and Event Schedule  
Study Phase  Screeninga Treatment   Follow -up 
Study 
Day/Week/Month  Day 
-14 to -1 Day 1  Day 7  
3 days Day 14 
3 days  Day 28  Week  6 Month  3 Month  7 Month  13h 
          
Informed Consent  X         
Demographics  X         
Medical Historyb, c X X X X X X X X X 
Physical examinationd X X   X X X X X 
Leishmanial History 
and Examc X    X X X X X 
Hematology  X         
Blood Chemistries Xe   Xf Xf Xg Xg Xg Xg 
ECG  X         
Pregnancy Test  X X X X X  X X  
Eligibility Checklist  X         
AEs  X X X X X X X X 
Treatment   Daily      
aScreening  includes the 14 -day period for conducting screening procedures prior to the first administration of investigation product  on 
Day 1.  
bIncludes medication history  
cIf subject  does not appear  at the scheduled Week 6, Month  3, Month 7, or Month 13 visits, these data may be obtained from the 
subject  by telephone, and will be noted as obtained in that manner.  
dIncludes vital signs  
eScreeni ng laboratories  
fAlanine  transaminase ( ALT ) and creatinine on D ay 28 and also on nominal day 14  
gIf abnormal on previous examination  
hML subject s only  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  7 
Version 1, March 6 , 2010  3 ABSTRACT  
The purpose of this Treatment Protocol is to make miltefosine immediately available for 
mucocu taneous leishmaniasis subject s presenting in the United States. Submission of an 
application for New Drug Approval is in process. Enrollment in this protocol makes it possible 
for subject s and their physicians to utilize miltefosine prior to approval.  
 
If entrance criteria are met, subjects with mucosal or cutaneous leishmaniasis will receive 
miltefosine at a targeted dose of 2.5 mg/kg/day for 28 days. During  the 28 -day treatment period, 
the subject  will return to the treatment facility at least three time s for evaluations and recording 
of any  AEs. Blood samples for the evaluation of transaminase and creatinine levels will be drawn 
at the midpoint and at the end of therapy.  
 
Subject s will return to the treatment facility to be examined clinically at Study Week 6 (i.e., 2 
weeks  after the end of therapy), Month 3  (2 months after therapy), and Month 7 (6 months after 
treatment) for mucosal leishmaniasis ( ML) and cutaneous leishmaniasis (CL) subject s. ML 
subject s will also be evaluated at Month 13 (12 months af ter treatment).  
 
OBJECTIVES  
Primary:  Record the efficacy of miltefosine, approximately 2.5 mg/kg/day for 28 days, in the 
treatment of mucocutaneous leishmaniasis presenting in the United States.  
 
Secondary:  Record the tolerance of miltefosine, approximate ly 2.5 mg/kg/day for 28 days, in the 
treatment of mucocutaneous leishmaniasis  presenting in the United States.  
 
STUDY DESIGN  
Open -label, single group, multicenter study.  
 
POPULATION  
1. Male or female at least 18 years of age.  
2. Weight at least 30 kg.  
3. Provided informed consent  
4. ML or CL already demonstrated in at least one lesion by at least one of the following 
methods:  
a. positive culture  of lesion material  for promastigotes ,  
b. microscopic identification of amastigotes in stained lesion tissue,  or 
c. PCR of lesion ma terial.  
5. No antileishmanial therapy in the previous  4 weeks.  
6. Subject capable of understanding and complying with the protocol.  
7. If female and of child -bearing potential, a negative pregnancy test during screening and 
agree to use an acceptable method of bir th control during the treatment phase and for 6 
months after treatment.  
8. If female, not breast feeding.  
9. No clinically significant medical disorder. Specifically:  
a. Platelet  count >100 x 109/L 
b. Leukocyte count >3 x 109/L 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  8 
Version 1, March 6 , 2010  c. Hemoglobin >10 g /dL 
d. ALT  <2 times upper l imit of normal range  
e. Bilirubin <1.5 times upper limit of normal range  
f. Serum creatinine  <1.5 times upper limit of normal range  
g. Major surgery within last 2 weeks  
h. Any non -compensated or uncontrolled condition  
10. No known Sjogren -Larssen syndrome  
 
INVESTIGATION AL PRODUCT  
Drug name:  Miltefosine (50 mg capsules).  
Dosing regimen:  Approximately 2.5 mg/kg/day (maximum: 150 mg per day) for 28 days.  
Dose:  The daily dosage for subject s of body weight 30 -45 kg is 100 mg miltefosine (2 capsules 
Impavido 50 mg). Subjec ts with a body weight higher than 45 kg receive 150 mg miltefosine 
daily (3 capsules Impavido 50 mg). The dose is administered orally, with meals.  
 
STUDY PROCEDURES  
Subjects with ML or CL from which Leishmania  have already been  identified are potentially 
eligible to be treated with miltefosine via this protocol. Treating Physicians with potentially 
eligible subject s will contact the protocol Principal Investigator (PI), and receive the case report 
forms ( CRF ) from the PI. The Treating Physician will complet e the  screening CRF pages for  
demographics, medical history, leishmaniasis history, clinical laboratory results  that are 
available , and identification of Leishmania  in the lesion, and send the  completed CRF pages  to 
the PI. If after PI review, the subject  is potentially eligible for the protocol, the PI will send the 
protocol, the miltefosine package insert,  the informed consent form , and a blank copy of FDA 
form 1572 to the Treating Physician. Although t his protocol will have already been approved by 
a “central” I nstitutional Review Board (IRB) , if there is an additional need to have the Treating 
Physician’s local IRB approve the protocol, the Treating Physician will obtain the approval, and 
obtain informed consent from the subject . The rest of the laborat ory tests must be accomplished 
so that a ll screening laboratory tests are completed prior to enrolling a potential subject . If in the 
physician’s opinion the subject  appears eligible  for enrollment, the Treating Physician will send 
to the PI the local IRB signature page (if needed ), protocol signature page , informed consent 
signed by both the subject an d the Treating Physician, the rest of the completed CRF  pages for 
screening , and the form 1572 completed with the Treating Physician’s information plus the 
Treating Physician’s curriculum vitae . After the PI’s review of the se forms , the investigational 
product will be sent from the drug repository to the Treating P hysician for that subject ’s use.  
 
Treatment will be daily for 28 consecutive days. During treatme nt at weeks 1, 2, and 4, the 
subject  will return to the treatment facility to be assessed for adverse events and to receive 
additional supply of medication if needed. Compliance with drug administration will be assessed 
by subject  interview and pill count.  Blood for transaminase and creatinine values will be drawn 
at the midpoint and at the end of therapy.  
 
Subject s will return to the treatment facility to be examined clinically at Study Week 6, Study 
Months 3 and 7 months for ML and CL subject s, and also at Study Month 13 for ML subject s.  
 
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  9 
Version 1, March 6 , 2010  SAMPLE SIZE AND STUDY DURATION:   
10-20 subject s per year for 1 -5 years.  
 
 
OUTCOME PARAMETERS:  
Efficacy: Clinical response of lesions  
Safety:    AEs 
 
ANALYSIS:   
Efficacy: The percent of subject s who have clinical cur e of all lesions will be calculated.  
Safety: The occurrence and severity of AEs will be described.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  10 
Version 1, March 6 , 2010  4 INTRODUCTION AND RAT IONALE  
4.1 Mucocutaneous L eishmaniasis  (Murray et al., 2005)  
4.1.1 Clinical S pectrum  
Sandflies inoculate the skin with flagellated Leishmania promastigotes, which invade or are 
phagocytosed by local and immediately recruited host cells. Within phagolysosomes of resident 
macrophages, surviving promastigotes transform and replicate as amastigotes, which infect 
additional macrophages either locally or in distant tissues after dissemination.  
 
Multiple Leishmania  species produce CL, primarily L. major, L. tropica, and L. (L.) aethiopica 
(Old world cutaneous leishmaniasis); L. infantum and L. chagasi (Mediterranean and Caspian sea 
regions);  and L. mexicana, L. (L.) amazonenesis, L. braziliensis, L. (V.) panamensis, L. (V.) 
peruviana, and L. (V.)  guyanensis  (New World CL).  
 
A papule typically begins at the sandfly bite, enlarges to a nodule,  and ulcerates over 1 –3 
months. Flat plaques or hyperkeratotic or wart -like lesions also develop in Old World disease. 
Subject s, including travelers and military personnel, first seek attention because of one to two, or 
sometimes several (up to dozens) non -healing skin lesions on nocturnally exposed skin. In Old 
World CL, most lesions are papules, nodules, or nodule -ulcers, whereas ulcerative lesions are 
most common in New World CL.  Disseminated lesions and localised lymphadenopathy 
preceding skin ulcers o ccur in Brazil. L. tropica  infection disseminates in that new papules can 
appear around a healed lesion (leishmaniasis recidivans).  
 
Mucosal dissemination of New World species ( L. braziliensis, L. panamensis, L. guyanensis ) 
occurs in 1 –10% of infections, d eveloping 1 –5 years after cutaneous leishmaniasis has healed, 
but sometimes coincident with active skin lesions; about 90% of subject s have a preceding 
cutaneous scar. ML typically begins with erythema and ulceration at the nares, proceeding to 
nasal septu m perforation and destructive inflammatory lesions. The latter can obstruct the 
pharynx or larynx and produce remarkable disfigurement. Mucosal disease is occasionally 
reported outside of Latin America, and can be acquired by travelers.  
4.1.2 Diagnosis  
Diagnosi s is routinely made microscopically by identification of amastigotes in biopsies, 
scrapings, or impression smears. Combination of microscopy and culture increases diagnostic 
sensitivity to more than 85%, and culture (or DNA analysis) allows species identif ication. 
Detection of parasite DNA in lesion material by polymerase chain reaction ( PCR ), although 
generally only performed in research settings, is usually most sensitive in the diagnosis of both 
cutaneous and mucosal leishmaniasis.  
4.1.3 Treatment with Classic al Agents  
Cutaneous disease heals by re -epithelialization with scarring. Most Old World lesions self -cure 
within 2 –4 months ( L. major ) or 6 –15 months ( L. tropica ). In New World CL, self -healing after 
3 months is rapid in L. mexicana  (~75%), but slow in L. braziliensis  (about 10%) and L. 
panamensis  infections (about 35%).  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  11 
Version 1, March 6 , 2010   
CL is treated to accelerate cure, reduce scarring especially at cosmetic sites, and to attempt to 
prevent dissemination (eg, mucosal disease) or relapse. Treatment is especially likely to be given 
for persistent lesions (>6 months) or lesions that are located over joints, multiple (5 –10 or more), 
or large (4 –5 cm or more). Classic treatment with parenteral antimony would probably be 
successful in CL in all regions; however, up to 20 daily i njections of this moderately toxic drug 
approximates the morbidity of self -healing disease itself.  
 
ML can produce potentially life -threatening inflammatory disease and must be treated. The 
standard regimen, 28 days of parenteral antimony, induces cure in  around 75% of cases of mild 
disease (nares only), but advanced disease responds less well. Amphotericin B can be used as 
rescue therapy.  
4.2 Miltefosine  
Miltefosine (hexadecylphosphocholine ) is a phosphatidylcholine analogue. The s tructural 
formula  of milte fosine is :  
 
  
The drug was registered in India  in 2002 and in Germany  in 2004 to treat visceral leishmaniasis.  
Miltefosine was registered in Columbia in 2005 to treat visceral and cutaneous leishmaniasis, 
and post 2005 to treat CL and ML in Bolivia and in many other countries in the Americas . As the 
only recognized oral agent for leishmaniasis, the years since 2005 have been spent in further 
studies of visceral leishmaniasis and other forms of leishmaniasis.  
4.2.1 Dosage and Administration  
Miltefosine is provi ded as capsules for oral administration, containing 50 mg of drug substance 
per capsule.  
 
List of excipients:  Collodial anhydrous silica, microcrystalline cellulose, lactose monohydrate, 
talc, magnesium stearate, gelatin, titanium dioxide, ferric oxide, pu rified water.  
 
Recommended dosage:  Approximately 2.5 mg/kg/day orally for 28 days. The daily dosage for 
subject s of body weight 30 -45 kg is 100 mg miltefosine (2 capsules Impavido 50 mg). Subject s 
with a body weight greater  than 45 kg receive 150 mg miltef osine daily (3 capsules Impavido 50 
mg).  
 
The capsules should be taken with meals. Subject s taking 2 capsules per day should take one 
capsule with the morning meal and with the evening meal. Subject s taking 3 capsules per day 
should take one capsule with the morning meal, the noon meal, and the evening meal.  
 
4.2.2 Contraindications  
 Hypersensitivity to the active sub stance or any of the excipients  
 Pre-existing severe dama ge of liver or kidney function  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  12 
Version 1, March 6 , 2010   Sjögren -Larsson -Syndrome  
 Pregnancy and women of childbearin g potential who do not use reliable contraception 
during and u p to 3 -6 months after treatment  
4.2.3 Warnings and Precautions  
Impavido is contraindicated in pregnancy. Women of childbearing potential have to use effective 
contraception during and up to 3 -6 months  after treatment. Vomiting/diarrhea are very 
common/common side effects of therapy with Impavido and can compromise the efficacy of oral 
contraception. The subject  must be informed by her physician of these symptoms and if 
necessary, suitable alternative m ethods of contraception must be used.  
 
Subject s with ALT  (liver function), serum creatinine,  and blood urea nitrogen  (BUN)  (renal 
function)  1.25 times above the normal range were generally excluded from the clinical studies. 
Thus, data from subject s with a bnormalities of liver and kidney function are not available.  
 
Treatment with Impavido may lead to an increase in serum creatinine. Kidney function must be 
evaluated in biweekly intervals. In subject s with clinically significant abnormality in kidney 
functi on, monitoring should be continued until normalization.  
 
Gastrointestinal symptoms such as nausea, vomiting, diarrhea, and a feeling of motion sickness 
are possible side effects of therapy with Impavido. The subject s must be instructed that in case of 
prolonged persistence of vomiting and diarrhea a sufficient fluid intake must be ensured, to avoid 
dehydration and consequently the risk of an impaired renal function.  
4.2.4 Adverse Reactions  
 
Organ system  Very Common  
>10% of subject s Common  
1-10% of pts    
Gastroi ntestinal  Nausea   
Vomiting Grade 1 -2* Motion sickness  
Diarrhea Grade 1*  
Headache  
Renal   Creatinine elevation  
Grade 1*   
*Grade = National Cancer Institute Common Terminology Criteria (CTC) grade  
4.2.5 Drug Interactions  
In vitro  investigations have shown that in teractions are unlikely with medications that are 
metabolized by cytochrome P450 or glucuronised or otherwise conjugated. However, the 
possibility of interactions with commonly used medicinal products cannot entirely be excluded.  
4.2.6 Use in Specific Population s 
Pregnancy:  There are not adequate data on the use of miltefosine in pregnant women. Studies in 
animals have shown reproductive toxicity. Impavido is contraindicated in pregnancy. Women of 
childbearing potential have to use effective contraception during and up to 3 -6 months after 
treatment. Vomiting/diarrhea are very common/common side effects of therapy with Impavido 
and can compromise the efficacy of oral contraception. The subject  must be informed by her 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  13 
Version 1, March 6 , 2010  physician of these symptoms and if necessary, su itable alternative methods of contraception must 
be used. The subject  has to be advised to immediately contact her physician for pregnancy 
testing as soon as there is any suspicion of pregnancy. If the test is positive, the physician and 
subject  must discu ss the risks associated with this pregnancy.  
 
Nursing mothers:  It is not known whether miltefosine is excreted in the milk. Impavido must not 
be used during lactation; otherwise breast feeding must be stopped.  
 
Geriatric use:  Few subject s of age 65 yrs or greater have been included in investigations.  
 
Renal impairment:  Subject s with kidney function tests (serum creatinine, BUN) 1.25 times 
above the normal range were generally excluded from the clinical studies. Thus, data from 
subject s with mild/moderate/se vere abnormalities of kidney function are not available.  
 
Hepatic impairment:  Subject s with liver function tests (AST) 1.25 times above the normal range 
were generally excluded from the clinical studies. Thus, data from subject s with 
mild/moderate/severe a bnormalities of hepatic function are not available.  
4.2.7 Clinical and Non -clinical Pharmacology  
4.2.7.1  Pharmacodynamic Properties  
Miltefosine has a marked direct antileishmanial activity in vitro  and in animal models. However, 
the relevance of specific values (ED50, E D90) to clinical efficacy is unknown. The specific 
mode of action of miltefosine in leishmaniasis is unknown. Among other possible mechanisms, 
miltefosine can inhibit the metabolism of phospholipids in cell membranes of parasites.  
 
Nonclinical Pharmacokine tic Studies  
Distribution studies in rats, using radioactively labeled miltefosine, showed highest uptake of 
radioactivity in kidney, liver and spleen. Slow elimination of radioactivity from tissues (half 
lives 8 -16 days) is partially explained by metabolis m of miltefosine and incorporation of the 
labeled choline fragment into physiological lipids.  
 
No oxidative metabolism by 15 different cytochrome P450 isozymes was observed in vitro . No 
CYP3A induction by miltefosine was found in vivo , in rats. Thus, no in teraction has to be 
expected between miltefosine and drugs, like contraceptive hormones, that are metabolized by 
CYP3A. A slow metabolic breakdown could be shown in human hepatocytes, resulting in the 
release of choline by phospholipase D like cleavage of the miltefosine molecule. The fatty 
alcohol containing fragment of miltefosine can enter the metabolism of fatty acids after being 
oxidized to palmitic acid. This oxidation is blocked in subject s with Sjögren -Larrson syndrome, 
which is caused by  a genetic defect in fatty alde hyde dehydrogenase activity.  Preclinical and 
clinical studies suggest that only a very minor part of the administered dose will be excreted as 
the unchanged drug substance. Instead, choline and choline -containing metabolites are the mos t 
likely excretion products.  
 
 
 
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  14 
Version 1, March 6 , 2010  Pharmacokinetic studies in subject s with cutaneous leishmaniasis (Dorlo et al., 2008)  
Subject s were administered miltefosine at an average dosage of 1.8 mg/kg/day. Pharmacokinetic 
analysis in this CL subject  population resulted in calculation of two half lives: a first half -life of 
7.0 days and a terminal half -life of 31 days.  
 
Nonclinical Toxicology  
Toxicological studies with miltefosine have been performed in mice, rats, dogs and ra bbits. 
Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar 
to clinical exposure levels and with possible relevance to clinic al use are described in the section 
below.  
 
Acute and Chronic Toxicity  
The oral admin istration of miltefosine in rats was associated with regressive and/or progressive 
lesions especially affecting the eyes (retinal degeneration), kidneys (acute resp. chronic 
nephropathy) and organs with rapidly dividing cell tissues (atrophy/hyperplasia), as well as 
reproductive organs (atrophy). These alterations were observed after 8 weeks treatment at doses 
of 10 mg/kg/day which led to plasma drug levels of about 52 μg/ml. Juvenile rats were more 
sensitive than adult rats to the miltefosine induced effec ts, especially on eyes and kidneys.  
 
Reproducti ve Toxicity  
Testicular atrophy and impaired fertility were observed in rats following daily oral doses of 8.25 
mg/kg. These findings were reversible within a recovery period of 10 weeks. Reproductive 
toxicity studies in rats during the early embryonic development (up to day 7 of pregnancy) 
indicate an embryotoxic, fetotoxic and teratogenic risk following miltefosine dosages of 1.2 
mg/kg/day and higher. Embryo - and fetotoxic findings were also observed in rabbit s after oral 
administration of miltefosine during the phase of organogenesis (2.4 mg/kg/day and higher).  
 
Mutagenicity/ Carcinogenicity  
Miltefosine tested negative in 6 of 7 of mutagenicity tests (AMES -Salmonella test, DNA -
amplification test, chromosomal ab erration test in vitro , UDS -test in vivo /in vitro , oral mouse -
micronucleus test in vivo ). The V 79 mammalian cell HPRT gene mutation test showed an 
increase in mutant frequency without dose dependency. In view of all mutagenicity test results, 
the single p ositive finding in the V 79 HPRT test is considered to be not of toxicological 
relevance with respect to a mutagenic risk to humans. The results of the mutagenicity tests ruled 
out a genotoxicity -mediated carcinogenic potential of miltefosine. Carcinogenic ity studies were 
not performed.  
4.2.8 Clinical Studies in Mucocutaneous L eishmaniasis   
In a dose -ranging study against L. panamensis  in Colombia, high rates of cure were seen in 
subject s treated with 2.5 mg/kg/day dose for 3 -4 weeks, the same regimen previously used for 
visceral leishmaniasis. The regimen of 2.5 mg/kg/day x 28 days was then evaluated in a placebo -
controlled  study in both Colombia against L. panamensis  and Guatemala against L. 
braziliensis/L . mexicana . Success in this placebo -controlled study led to continent -wide and 
world -wide use of miltefosine for all forms of leishmaniasis.  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  15 
Version 1, March 6 , 2010  Further studies in the New W orld have been reported for Bolivian CL and Bolivian ML due to L. 
braziliensis  and against Venezuelan diffuse cutaneous leishmaniasis due to L. amazonensis . 
4.2.8.1  Dose -finding S tudy in L. panamensis  Region in Colombia  (Soto et al. , 2001)  
The cure rate for evaluable subject s in group 1 (50 mg miltefosine/day) was 9/14 (64%). The 
cure rate in group 2 (100 mg miltefosine/day) was 12/18 (67%). The cure rate in subject s given 
150 mg miltefosine/day [2.5 mg/kg/day for these subjects of average weight of 67 kg] was 14/14 
(100%) for subject s treated for 20 days in group 3 and 16/18 (89%) for subject s treated for 28 
days in group 4. Because a larger total dose of drug should be more effective in the general 
population, the dose of a pproximately 2.5 mg/kg/day for 28 days was adopted based on this 
study.  
4.2.8.2  Placebo C ontrolled Study in L. panamensis  Region in Colombia and in L. 
braziliensis/L . mexicana Region in Guatemala (Soto et al., 2004)  
The obj ective of this study was to demonstrate that miltefosi ne, 2.5 mg/kg/day for 28 days, was 
superior to placebo in cutaneous leishmaniasis in male or female subject s >12 yrs when assessed 
6 months after end of treatment. The per protocol cure rate against L. panamensis  in Colombia 
was 91% ( Table 1 below), in conformity to the results from groups 3 and 4 of the dose -ranging 
study #3092, and statistically higher than the cure rate for placebo (38%).  
 
Table  1.  Efficacy of Miltefosine Used to Treat CL  in Colombi an and Guatemalan Subject s 
 
Variable  Colombian site  Guatemalan site  
Miltefosine 
recipients    
(n = 49)  Placebo 
recipients    
(n = 24)  Miltefosine 
recipients    
(n = 40)  Placebo 
recipients    
(n = 20)  
No. of subject s cured  40 9 20 4 
No. of subject s with  treatment failure      
    All 4 15 18 15 
    Parasite -positive lesions  0 15 12 12 
    Size of lesion doubled  2 5a 4b 2 
    Relapse  2 0 4 1 
No. of unassessable subject s     
    All 5 0 2 1 
    Lost after therapy  2 0 1 1 
    Lost after 2 weeks  2 0 1 0 
    Lost after 3 months  1 0 0 0 
Cure rate, n/N (%)      
    Intent -to-treat 40/49 (82)  9/24 (38)  20/40 (50)  4/20 (20)  
    Per-protocol  
  40/44 (91)  9/24 (38)  20/38 (53)  4/19 (21)  
a All 5 of these subject s also had parasite -positive lesions.  
b Two of  these 4 subject s also had parasite -positive lesions.  
Table adapted from Soto et al., 2004 . 
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  16 
Version 1, March 6 , 2010  The cure rate was comparable to that historically achieved for pentavalent antimony in 
Colombia. Although the per protocol cure rate in Guatemala (53%) was statis tically higher than 
placebo cure rate (21%), the cure rate against L. braziliensis  in this locale was less than that 
historically achieved for penta valent antimony in Guatemala (> 90%).  
 
Because this study was placebo -controlled, the rate of subjective and laboratory AEs specifically 
due to miltefosine can be determined. The percent of subject s with noteworthy subjective AEs, 
and with abnormal laboratory findings, is shown in Table 2  below:  
  
Table  2.  Subject  Demographics and E fficacy results (Soto et al., 2008)  
 
Variable  No. (%) of subject s 
Miltefosine 
recipients     
(n = 89)  Placebo      
(n = 44)  
Treatment -emergent AEs   
    Nausea  32 (36)  4 (9)a 
    Motion sickness  26 (29)  10 (23)  
    Headache  24 (27)  9 (20)  
    Vomiting    
        ≥ 1 28 (31)  2 (5)a 
        1-2 22 (25)  1 (2) 
        3-4 3 (3)  1 (2)  
        >4 3 (3)  0 (0)  
    Diarrhea    
        ≥1 5 (6)  1 (2) 
        1-2 4 (4)  1 (2)  
        >2 1 (1)  0 (0)  
Laboratory parameters    
    Creatinine level    
        Increased  29 (33)  4 (9)b 
        CTC grade 1c 28 (31)  4 (9)  
        CTC grade 2d 1 (1)  0 (0)  
Elevated alanine  aminotransferase level  7 (8)  8 (18)  
Elevated alanine aminotransferase level  9 (10)  5 (11)  
ap<0.001  
bp=0.003 
cless than 1.5 times the upper limit of normal  
dless than 1.5 and 3.0 times the upper limit of normal  
 
This placebo -controlled study of 89 miltefosine subject s shows that in humans who are without 
systemic disease, nausea and vomiting but not diarrhea occur significantly more  frequently than 
in placebo subjects, and elevation of serum creatinine but not ALT  occurs significantly more 
frequently than in placebo subjects. Most of the miltefosine -specific AEs were of mild severity: 
80% of the episodes of vomiting were CTC grade 1;  97% of the creatinine elevations were CTC 
grade 1.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  17 
Version 1, March 6 , 2010  4.2.8.3  Comparison of M iltefosine to Pentavalent Antimony in L. braziliensis  Region in 
Bolivia (Soto et al., 2008)  
The subject s were randomized to treatment with miltefos ine (2.5 mg/kg/d for 28 days) or to a 
standard course of intramuscular pentavalent antimony (Glucantime: 20 mg/kg/d for 20 days) in 
2:1 allocation.  
 
AEs were as expected for the two drugs. The primary AE for the miltefosine group was 
gastrointestinal symp toms, which were experienced by 27 of 44 subject s (61%) for a median of 3 
days (range, 1 –10 days). For the glucantime group, 13 of 18 subject s (72%) reported arthralgias 
and/or local pain at the injection site for a median of 7 days (range, 5 –14 days).  Efficacy data is 
presented in the Table  3 below.  
 
Table 3.  Subject  Demographics and Efficacy Results (Soto  et al. , 2008)  
 
  
  Miltefosine 
recipients  Glucantine 
subject s 
Presenting characteristics    
    Number of subjects 44 18 
    Age of subject s [years; median   (range)]  27 (12 -57) 23 (12 -51) 
    Male/Female  36/8 15/3 
    Weight of subject s [kg; median (range)]  59 (39 -78) 59 (38 -80) 
    Number of ulcers  64 30 
      Number per subject  [median (range)]  1 (1-3) 1 (1-3) 
      Area (mm2) [median (range)]  181 (10 -3,172) 150 (4 -900) 
Results    
    End treatment    
      No. of subject s healed/failed/lost  15/0/0  9/0/1  
      Percent of subject s healed/evaluable  15/44 =34% 9/17=53%  
    1 month after treatment    
      No. of subject s healed/failed/lost  31/0/0  16/0/2  
      Percent of subject s healed/evaluable  31/44=70%  16/16=100%  
    3 months after treatment    
      No. of subject s healed/failed/lost  39/4/1  15/1/2  
      Percent of subject s healed/evaluable  39/43=91%  15/16=94%  
    6 months after treatment    
      No. of subject s healed/failed/lost  36/5/3  15/1/2  
      Percent of subject s healed/evaluable  36/41=88%  15/16=94%  
*P=0.01 (Fisher exact test).  
 P=0.67 (Fisher exact test).  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  18 
Version 1, March 6 , 2010  The final cure rate for miltefo sine (88%) was insignificantly less than the value for pentavalent 
antimony (94%), although antimony was more rapidly curative since the cure rate at 1 month 
after therapy was higher for antimony (10 0%) than for miltefosine (70%). This comparator -
controlle d study vs. L. braziliensis  in Bolivia shows that the relative lack of efficacy of 
miltefosine for L. braziliensis  in Guatemala may be an outlier.  
4.2.8.4  Single -arm Study on Diffuse C utaneous Leishmaniasis (DCL) in Venezuela (Zerpa 
et al., 2007)  
DCL is essentially untreatable because of an inappropriate immunological response by the host 
to parasite antigens. Sixteen subject s with DCL refractory to multiple previous treatments were 
treated with miltefosine, 2.0 –2.5 mg/kg da ily, for long periods of time (75 –218 days).  
 
AEs were very mild. Side -effects were observed in four subject s; two complained of nausea and 
vomiting and reduced the dose without consultation, with improvement in symptoms. One 
subject  presented with dizzin ess on the second day of treatment. On day 20 one subject  presented 
with urticaria, that improved with systemic antihistamines. None presented with alteration of 
laboratory parameters during the study.  
 
Subject s showed dramatic clinical improvement and red uction in the parasite burden by day 15 
after the initiation of treatment, which continued while treatment was maintained. By day 45, 15 
subject s showed 80 –90% clinical improvement. Nevertheless, suspension of treatment was 
followed by the development of n ew lesions between 30 and 120 days later in all but one subject .  
This study shows that miltefosine treatment can be tolerated for months beyond the normally 
recommended period of 4 weeks.  
4.2.8.5  Mucosal Leishmaniasis (Soto  et al., 2007)   
The initial study design was a randomized equivalency study of oral miltefosine (50 subject s) 
versus standard therapy with pentavalent antimony (25 subject s).  Due to changes in regional 
standard of care to amphotericin B (45 mg/kg as 1mg/ kg doses for 45 consecutive days), and due 
to initial positive response rates in the miltefosine group, subject s refused to be treated with 
antimony or to be randomized to the amphotericin B arm of the study. Therefore, the final study 
design became an eva luation of one cohort of 78 subject s who received miltefosine (2.5 
mg/kg/day for 28 days). An almost contemporary group of 19 subject s who received 
amphotericin B (45 mg/kg) as miltefosine treatment was getting organized was evaluated as a 
post hoc compari son group.  
 
Miltefosine was well tolerated. Nausea, vomiting, and diarrhea were each reported by 8 –17 
subject s. Most episodes were CTC grade 1; one episode was grade 3. Most episodes lasted 1 –2 
days and a few lasted 3 –4 days. Mean values of liver function tests and kidney function tests did 
not change; a few subject s had values that were slightly above the upper limit of normal after 
treatment.  
 
Of the 78 subject s who received miltefosine, 72 were evaluable. Fourteen of 19 subject s in the 
amphotericin B gro up were evaluable. Fifty -one (71%) of the 72 evaluable miltefosine subject s 
were “cured” by the definition of >90% diminution in the mucosal severity score with 12 months 
of follow up. Almost all (49 [96%]) of these subject s demonstrated complete resolutio n of their 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  19 
Version 1, March 6 , 2010  clinical signs. The cure rate for the 36 subject s who had “mild” disease (i.e., affecting only the 
nasal skin and nasal mucosa) was 83%. The cure rate for the 36 subject s who had more extensive 
disease (involving the palate, pharynx, and larynx)  was 58%.  
 
The cure rate for the amphotericin B group (45 mg/kg over 90 days) was 7 (50%) of 14.  
Since the historic cure rate for treatment of ML in neighboring Peru varies between 10% and 
75%, this study suggests that miltefosine is approximately as effe ctive as standard treatment with 
antimony, and with amphotericin B, for Andean mucosal disease.  Before -and-after photographs 
of one subject  from this study with involvement of the external nares ( Figure 1 ), illustrates the 
clinical improvement in skin and mucosa consequent to successful miltefosine therapy.  
 
4.2.8.6  Clinical Summary  
The cure rate for CL treated with miltefosine (2.5 mg/kg/day for 28 days) is superior to placebo 
and, except in one region, comparable to standard therapy with antimony. This regimen of 
miltefosine also gives cure rates for ML comparable to historic values for antimony, and 
provides remarkable clinical improvement for DCL subject s. 
   
Subject s with CL or ML are systemically normal. For these hosts, laboratory abnormalities due 
to milte fosine treatment consist of the common occurrence of low grade elevations in serum 
creatinine, and the uncommon occurrence of higher -grade elevations, both of which are 
reversible. The symptoms of nausea, vomiting, and perhaps motion sickness /headache  are also 
common.  
  
Miltefosine has a favorable therapeutic index for CL and ML, with the additional advantage of 
being orally administrable. No other accepted antileishmanial agent, whether an investigational 
agent in the United States or registered agent else where, is orally administrable.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  20 
Version 1, March 6 , 2010  4.2.9 References  
 
Investigator's Brochure. Edition 15 January 2009. Paladin Labs Inc.  
 
Dorlo, T. P., P. P. van Thiel , et al.  (2008). Pharmacokinetics of miltefosine in Old World 
cutaneous leishmaniasis patien ts. Antimicrob Agents Chemother  52(8): 2855 -60. 
 
Murray, H. W., J. D. Berman , et al.  (2005). Advances in leishmaniasis. Lancet  366(9496): 1561 -
77. 
 
Soto, J., J. Toledo , et al.  (2001). Treatment of American cutaneous leishmaniasis with 
miltefosine, an oral agent. Clin Infect Dis  33(7): E57 -61. 
 
Soto, J., B. A. Arana , et al.  (2004). Miltefosine for new world cutaneous leishmaniasis. Clin 
Infect Dis  38(9): 1266 -72. 
 
Soto, J., J. Toledo , et al.  (2007). Treatment of Bolivian mucosal leishmaniasis with miltefosin e. 
Clin Infect Dis  44(3): 350 -6. 
 
Soto, J., J. Rea , et al.  (2008). Efficacy of miltefosine for Bolivian cutaneous leishmaniasis. Am J 
Trop Med Hyg  78(2): 210 -1. 
 
Zerpa, O., M. Ulrich , et al.  (2007). Diffuse cutaneous leishmaniasis responds to miltefosine b ut 
then relapses. Br J Dermatol  156(6): 1328 -35. 
 
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  21 
Version 1, March 6 , 2010  5 STUDY OBJECTIVES  
5.1 Primary  
Record the efficacy of miltefosine, 2.5 mg/kg/day for 28 days, in the treatment of 
mucocutaneous leishmaniasis presenting in the United States.  
5.2 Secondary  
Record the tolerance of miltefosine, approximately 2.5 mg/kg/day for 28 days, in the treatment 
of mucocutaneous leishmaniasis presenting in the United States.  
6 STUDY DESIGN  
Open -label, single group, multicenter study  
7 STUDY SUBJECTS  
7.1.1 Estimated N umber of Subjects  
10-20 per year for 1 -5 years  
7.1.2  Inclusion Criteria  
To be eligible for the study, the following must be answered “YES” or not applicable as 
appropriate for the study subject:  
 
1. Is the subject a male or female at least 18 years of age?  
2. Does the subject weight at least 30 kg?  
3. Does the subject have a diagnosis of ML or CL in at least one lesion by at least one of the 
following methods:  
a. positive culture of lesion material for promastigotes,  
b. microscopic identification of amastigotes in stained lesion tissue,  or 
c. PCR of lesion material ?  
4. In the opinion of the investigator, is the subject capable of understanding and complying 
with the protocol?  
5. If female and of child -bearing potential, did the subject have a negative pregnancy test 
during screening and agree to use an acceptable method of birth control during the 
treatment phase and for 6 months after treatment is completed?  
6. Has the subject  signed informed consent?  
7.1.3 Exclusion Criteria  
To be eligible for the study, the following must be answered “NO” or not applicable as 
appropriate for t he study subject:  
  
1. Is the subject a female who is breast -feeding?  
2. Does the subject have a clinically significant medical disorder?  
a. Platelet  count <100 x 109/L 
b. Leukocyte count <3 x 109/L 
c. Hemoglobin <10 g/ dL 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  22 
Version 1, March 6 , 2010  d. ALT , >2 times upper limit of normal range  
e. Bilirub in >1.5 times upper limit of normal range  
f. Serum creatinine  >1.5 times upper limit of normal range  
g. Major surgery within last 2 weeks  
h. Any non -compensated or uncontrolled condition  
 
3. In the last 4 weeks up to the present, has the subject received other treatm ent for 
leishmaniasis, including any medication with pentavalent antimony; amphotericin B, 
paromomycin, or imidazoles?  
8 INVESTIGATIONAL PROD UCT  
8.1 Description  
Miltefosine is formulated as capsules of 50 mg strength. The ingredients are as follows:  
 
 Active Principle:  50 mg miltefosine  
Inactive ingredients:  Lactose D10, avicel PH 101, talkum, aerosil V200, magnesium   
stearate  
 
The investigator or authorized person assigns the box to an eligible subject  by writing the 
subject ’s study number and alpha code o n the label on the box, i.e. capsules in a box are for use 
in a single subject  only; residual capsules may not be used for another subject . The trial 
medication may not be used after the retest or expiry date which is specified in the certificate of 
analys is.  
8.2 Labeling  
Each box of miltefosine contains 56 capsules: 8 packs of blisters, with each blister pack 
containing 7 capsules. Each box has a  preprinted label with a space for the subject’s ID number, 
alpha code, dosing instructions, 24/7 emergency telepho ne number, storage conditions, 
precautions, and lot# and expiry date, as follows:  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  23 
Version 1, March 6 , 2010   
 
Each blister pack is preprinted with “Impavido 50 mg capsules” as well as other identifying 
information.  
8.2.1 Storage  
Medication should be kept out of the reach of children and away from direct sun light, and at 
temperatures not above 40 C (104F).  
8.2.2 Drug Accountability  
The Treating Physician has to account for all used and unused trial supplies and has to complete 
a Medication Accountability Form . Res idual supplies will be destroyed by the Treating 
Physician as directed. The completed Medication Accountability Form will be returned to the 
Data -Management Center . The trial medication must not be used outside this protocol.  
8.3 Start of T reatment  
Treatment should be started within 2 weeks after the completion of screening assessments. 
Otherwise compliance with eligibility criteria has to be reassessed.  
8.4 Administration of Investigational Product  (Miltefosine)  
Route:   Oral administration  
 
Dose:    The daily dos age for subject s of body weight 30 -45 kg is 100 mg miltefosine (2 capsules 
Impavido 50 mg). Subject s with a body weight higher than 45 kg receive 150 mg miltefosine 
daily (3 capsules Impavido 50 mg).  
 
The capsules should be taken with meals. Subject s taki ng 2 capsules per day should take one 
capsule with the morning meal and with the evening meal. Subject s taking 3 capsules per day 
should take one capsule with the morning meal, the noon meal, and the evening meal.  
 Clinical Study # P LB-MILT -201           Sponsor: Paladin Labs (USA) Inc.  
 
ID #    _____________________          Alpha code  ___________________  
  
Take 1 capsule ____ times a day with meals  
 
If medical emergency, call your doctor at (         ) ________________  
 
Store in original container at room temperature  
 
CAUTION: INVESTIGATIONAL NEW DRUG LIMITED BY FEDERAL 
LAW TO INVESTIGATIONAL USE.  
 
Caution: K eep out of the  reach of children  
 
Lot #   8J7717                                    Expiry Date: 10 July  2012  
 
Manufactured by: Haupt Pharma Amareg GmbH, Regensburg, Germany  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  24 
Version 1, March 6 , 2010  Duration of treatment:   28 days.  
8.5 Allocat ion of Study Treatment to Subject  and Compliance  
For subject s who will receive 2 capsules per day, the subject  will receive a box of medication (56 
capsules) at the initiation of therapy which is sufficient for the total treatment period of 28 days. 
For subject s who will receive 3 capsules per day, the subject  will receive a box of medication (56 
capsules) at the beginning of therapy that is enough for 18 days of treatment, and will return to 
the treatment facility after 2 weeks to receive the final 2 week’ s supply of medication.  
Compliance with drug administration will be assessed by subject  interview and pill count.  
8.6 Treatment M odifications and Study Discontinuation  
Dose reduction due to AEs: A subject  who does not tolerate the planne d dosage will go off -
treatment. N o dose reduction is planned.  
 
Discontinuation of study treatment and withdrawal from protocol for other reasons:   A subject 
may withdraw from the study at any time and for any reason without penalty, if he or she wishes 
to do so.  The Treating Physician may withdraw a subject if continuing participation is believed 
to be harmful to the subject’s well -being or in the event of protocol violations, non -compliance, 
positive pregnancy test during active treatment, serious intercurrent illness, or app arent failure of 
efficacy. The sponsor, PI, and IRB have the right to discontinue the investigation at any time.  
 
In the event that the subject withdraws from the study before the completion of the 28 days of 
treatment, s/he will be asked to come to the cl inic for a final assessment including AEs, lesion 
measurements, vital signs, blood creatinine, and concomitant medication use.  
 
If the subject withdraws during the follow -up period, s/he will be contacted, if possible, and 
requested to come to the clinic for lesion measurements.  
 
If possible, positive pregnancy should be followed to the end of the pregnancy.  
8.7 Concomitant Therapy  
All concomitant medications and any therapies (prescribed and non -prescribed) must be recorded 
on the CRF . Any change during the  study should be documented as well. Symptomatic treatment 
of side effects and treatment of concomitant diseases not associated with leishmaniasis is 
permitted.  Treatment with other agents known or likely to be active against Leishmania 
(pentavalent antimo ny, amphotericin B, paromomycin,  imidazoles, local heat or cold therapy)  is 
not permitted . 
8.8 Rescue Treatment   
Anti-leishmaniasis drugs must not be administered while the subject  is on protocol. If the subject  
is removed fr om the protocol for any reason ( decision that the subject  has failed treatment, 
inability of the subject  to comply with the protocol conditions, or desire of the subject , physician, 
Sponsor, or IRB) , the subject  may be treated with another antileishmanial agent off -protocol at 
the discreti on of the treating physician.  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  25 
Version 1, March 6 , 2010  9 STUDY PROCEDURES  
 
Time and Event Schedule  
Study Phase  Screeninga Treatment  Follow -up 
Study 
Day/Week/Month  Day 
-14 to -1 Day 1  Day 7  
3 days Day 14 
3 days  Day 28  Week  6 Month  3 Month  7 Month  13h 
          
Informed Consent X         
Demographics  X         
Medical Historyb, c X X X X X X X X X 
Physical examinationd X X   X X X X X 
Leishmanial History 
and Examc X    X X X X X 
Hematology  X         
Blood Chemistries Xe   Xf Xf Xg Xg Xg Xg 
ECG  X         
Pregnancy Tes t X X X X X  X X  
Eligibility Checklist  X         
AEs  X X X X X X X X 
Treatment   Daily      
aScreening includes the 14 -day period for conducting screening procedures prior to the first administration of investigation product  on 
Day 1.  
bIncludes medica tion history  
cIf subject  does not appear  at the scheduled Week 6, Month  3, Month 7, or Month 13 visits, these data may be obtained from the 
subject  by telephone, and will be noted as obtained in that manner.  
dIncludes vital signs  
eScreening laboratories  
fAlanine transaminase (ALT) and creatinine on D ay 28 and also on nominal day 14  
gIf abnormal on previous examination  
hML subject s only  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  26 
Version 1, March 6 , 2010  9.1 Subject  Recruitment  
The medical community will be alerted to the availability of miltefosine via this Treatment IND 
via informal communications and listing on ClinicalTrials.gov.  
 
Subjects with mucosal or cutaneous lesions from which Leishmania  have already been  identified 
are potentially eligible to be treated with miltefosine via this protocol. Treating Physicians with 
potentially eligible subjects will contact the protocol PI, and receive the CRF s from the PI. The 
Treating Physician will complete the screening CRF pages for demographics, medical history, 
leishmaniasis history, clinical laboratory results that are availabl e, and identification of 
Leishmania  in the lesion, and send  (mail or fax)  these CRF pages  to the PI. If after PI review, the 
subject is potentially eligible for the protocol, the PI will send the protocol, the miltefosine 
package insert, the informed conse nt form , and the FDA form 1572  to the Treating Physician. 
Although this protocol will have already been approved by a “central” IRB, if there is an 
additional need to have the Treating Physician’s local IRB approve the protocol, the Treating 
Physician will  obtain the approval, and obtain informed consent from the subject. The rest of the 
laboratory tests must be accomplished so that all screening laboratory tests are completed prior to 
enrolling a potential subject. If in the physician’s opinion the subject  appears eligible for 
enrollment, the Treating Physician will send  the local IRB signature page (if needed), protocol 
signature page, informed consent signed by both the subject and the Treating Physician, the rest 
completed CRF pages for screening data to  the PI , and the form 1572 completed with the 
Treating Physician’s information plus his/her curriculum vitae . After the PI’s review of the se 
documents , the investigational product will be sent from the drug repository to the Treating 
Physician for that sub ject’s use.  
 
Note that because the tests needed to satisfy the entrance criteria of medical history, 
leishmaniasis history, and identification of Leishmania in the lesion are standard of care for this 
disease, the tests can be performed prior to signing th e consent form for this protocol. This 
procedural order [evaluate certain entrance criteria, then achieve local IRB approval if needed 
and signing of consent, then evaluate the rest of the entrance criteria] is chosen so that subject s 
do not undergo excess  procedures and expectations  if the subject  ultimately is unlikely to be 
able to enroll in the protocol.  
9.2 Screening Procedures  
Subject s will have the following procedures performed during a two week period prior to the  
initiation of investigational produc t: 
1. Consent form completed and signed.  
2. Demographics  form completed.  
3. Medical history form completed and record medications used in the past 2 weeks.  
4. Physical examination  form completed including vital signs, height, and weight.  
5. Leishmaniasis history and phys ical form completed.  
a. Record history of leishmaniasis including;  
(1) CL:   estimated date that the lesion(s) first appeared, evolution of symptoms, 
treatments to date  
(2) ML:  estimated date that the symptoms first appeared, evolution of symptoms, 
treatm ents to date  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  27 
Version 1, March 6 , 2010              b.  CL subject  examination: For each cutaneous lesion, record the size of the lesion 
ulceration (length/width), characteristics of the lesion (ulcerated versus non -
ulcerated), and anatomical location. Examination of nasal skin, nas al mucosa, palate, 
and pharynx must be performed by the Treating Physician . 
c.  ML subject  examination: Examination of mucosal membranes. Each of 5 possible 
sites (nasal skin, nasal mucosa, palate, pharynx, and larynx) will be evaluated for 4 
possible sign s of disease (erythema, edema, infiltration, and  erosion) by an ear, nose, 
and throat (ENT)  specialist.  
6. Pregnancy test from completed for women of child -bearing potential.  
7. Hematology  form completed to include white blood cells (WBC), neutrophil count, 
hemo globin, hematocrit, and platelet count.  
8. Chemistry  form completed including glucose, sodium, potassium, creatinine, ALT , and 
bilirubin in the serum . 
9.3 Assessment During M iltefosine Treatment  
9.3.1 Study Day 1  
Study Day 1 visit is conducted on the first day of milte fosine therapy  and includes:  
1. Medical H istory  - record changes in medical history or medications since screening visit 
2. Physical Examination  form - perform brief physical exam including vital signs  
3. Pregnancy test  form - perform a pregnancy test in women of c hild bearing potential, 
unless the screening pregnancy test was performed within the previous 24 hours.  
4. Complete the eligibility checklist to ascertain i f the subject still meets all of the eligibility 
criteria, then the subject  will rece ive the first dose  of medicine . 
5. Record any AEs  
9.3.2 Study D ays 7 and 14  
Two visits are scheduled to occur between Study Day 2 through Study Day 27 and should 
preferably occur at the end of Study Week 1 and Study Week 2  with in a three -day window 
either side of Day 7 and Day 14 . At these two visits the following assessments are performed:  
1. Medical History - The subject  will return to clinic for evaluation; record any AEs 
2. Treatment  form – complete log  
3. If more medication than that which was dispensed on day 1 is needed, further medic ation 
will be dispen sed on the nominal day 14 visit  
4. Chemistry – record v alues of ALT  and creatinine in the serum  (Day 14 visit only)  
5. Record any AEs  
9.3.3 Study Day 28  
Study Day 28 visit is conducted  the last day of miltefosine therapy  and includes:  
1. Medical Histo ry - record changes in medical history or medications  
2. Physical examination – record v ital signs  
3. Interval History of leishmaniasis:  
a. CL - lesion reactions  
b. ML - evolution of symptoms  
4. CL subject s: Re -examination of each CL lesion and re -recording the size of t he lesion 
ulceration (length/width), other notable characteristics of the lesion  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  28 
Version 1, March 6 , 2010  5. ML subject s: Re -examination of mucosal membranes  
6. Pregnancy test in w omen of child -bearing potential  
7. Chemistry  – record v alues of ALT  and creatinine in the serum  
8. Record any AEs  
9.3.4 Study Week 6  
Two weeks after the Study Day 2 8 visit reco rd the following:  
1. Medical History - record changes in medical history or medications since 28 -day visit  
2. Physical examination  - perform brief physical exam if appropriate, and vital signs  
3. Interval His tory of leishmaniasis since last visit to include:  
a. ML - re-examination of mucosal membranes. Evolution of symptoms  
b. CL subject s - re-examination of each CL lesion and record  the size of the lesion 
ulceration (length/width), other notable characteristics of the lesion  
4. ALT  and c reatinine : Repeat if abnormal on last examination  
5. Record any AEs  
9.3.5 Study Month 3  
Study Month 3 visit is conducted  2 months after the end of miltefosine therapy  and includes:  
1. Medical H istory  - record changes in medical history or medicati ons since 6 -week visit  
2. Physical Examination  - perform brief physical exam if appropriate, and vital signs  
3. Interval History of leishmaniasis since last visit to include:  
a. ML - re-examination of mucosal membranes. Evolution of symptoms.  
b. CL subject s - re-exami nation of each CL lesion and record the size of the lesion 
ulceration (length/width), other notable characteristics of the lesion  
4. Pregnancy test in women of child bearing potential  
5. ALT  and creatinine : Repeat if abnormal on last examination  
6. Record any AEs  
9.3.6 Study Month 7  
Study Month 7 visit is conducted 6 months after the end of miltefosine therapy. Final follow up 
visit for CL subject s and includes:  
1. Medical H istory - record changes in medica l history or medications since 3-month visit  
2. Physical Examination - perform brief physical exam if appropriate, and vital signs  
3. Interval History of leishmaniasis since last visit to include:  
a. ML - re-examin ation of mucosal membranes . Evolution of  symptoms   
b. CL subject s - re-examination of each CL lesion and record the size of the lesion 
ulceration (length/width), other notable characteristics of the lesion  
4. Pregnancy test in women of child bearing potential  
5. ALT  and creatinine : Repeat if abnormal on last examination  
6. Record any AEs  
9.3.7 Study Month 13  
Study Month 13 visit is conduc ted 12 months after the end of miltefosine therapy. Final follow 
up visit for ML subject s and includes:  
1. Medical H istory - record changes in medical  history or medications since 7 -month visit  
2. Physical Examination - perform brief physical exam if appropriate , and vital signs  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  29 
Version 1, March 6 , 2010  3. Interval History of leishmaniasis since last visit to include:  
a. ML - re-examination of mucosal membranes . Evolution of symptoms.   
b. CL subject s - re-examination of each CL lesion and record the size of the lesion 
ulceration (length/width), o ther notable characteristics of the lesion  
4. ALT  and creatinine : Repeat if abnormal on last examination  
5. Record any AEs  
 
NOTE: if the subject  does not return to clinic for the post -treatment visits, medical history and 
interval history of leishmaniasis may b e obtained by telephone. Further, the subject ’s 
examination of a CL lesion may be obtained by telephone. Telephonic data will be noted as such 
on the CRF.  
 
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  30 
Version 1, March 6 , 2010  10 EFFICACY  
NOTE: Re sponses in subject s with CL and ML will be presented separately.  
10.1 Efficacy Assessm ents of CL Subjects  
10.1.1  Assessment M ethods  
10.1.1.1  Parasitological D iagnosis of Leishmaniasis  
Prior to entrance into this protocol, lesion(s) will have been scraped, aspirated, or biopsied; and 
the specimens will have been smeared onto microscope slides for examinatio n with DifQuik or 
Giemsa staining, placed in culture medium to visualize motile promastigotes, or subjected to 
PCR analysis for Leishmania -specific nucleic acid.  
 
NOTE: The Treating Physician may choose to perform these parasite diagnostic procedures on 
lesions that are not -healed post therapy or on a new lesion to see if the lesion contains 
Leishmania . These procedures are at the Treating Physician’s discretion and not formally part of 
this protocol.  
10.1.1.2  Examination of Cutaneous L esions  
Ulcerated CL lesions will be measured in mm for the longest diameter and perpendicular width 
of ulceration. Non -ulcerated lesions will be measured for length and width of the raised area of 
the lesion. Lesion area = Length x Width. Lymph nodes in the drainage path of the cutan eous 
lesion will be noted and measured.  
10.1.1.3  Examination of M ucosa  
For CL subject s, the Treating Physician will examine the nasal and oral mucosa of each subject.  
10.1.2  Definitions of Lesion Response  
Healed:   100% reduction in lesion area [lesion size = 0x0 mm2] 
Improved:   50% - 99% reduction in lesion area  
No change:  49% enlargement to 49% reduction in lesion area  
Worse:   >50% enlargement of lesion area at or after the end of therapy.  
Relapsed:  Substantial enlargement of lesion after initial improvement or healing.  
 
10.1.3  Definition of Clinical Responses  
Lesion Cure:   Lesion is healed at the M onth 7  visit.  
Lesion Failure:  Each lesion will be considered a failure if it does not meet the criteria for cure 
(missing data will be considered failures). The intended response to t herapy is a progressive 
diminution in lesion size and no relaps e. Lesion failure therefore is defined as clinically worse at 
the end of ther apy or thereafter, OR does not i mprove at the Week 6  or Month 3 visit, OR is not 
healed at the  Month 7  visit, OR rel apses.  
 
NOTE: Parasitological responses can assist the clinician in evaluating the clinical response of the 
lesion. If the Treating Physician has parasitologically re -investigated a slowly responding lesion 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  31 
Version 1, March 6 , 2010  at time -points greater than 2 weeks after the en d of therapy, and parasites are still present by 
microscopy or culture, the physician may interpret the data as indicating therapeutic failure. Note 
that the presence of parasites prior to 2 weeks after the end of therapy should not be interpreted. 
Note th at because PCR is more sensitive than microscopy or culture on which the clinical 
experience in the literature is based, PCR positivity post therapy cannot easily be interpreted.  
10.1.4  Definition of Subject  Cure  
Subject  Cure:  All lesions cured  by the end of follow up at Month 7 visit .  
Subject  Failure:   Not all lesions clinically cure d, or a new lesion due to Leishmania . 
 
Primary endpoint(s) :  The co -primary endpoints are the subject  cure rate for the  modified 
intent ion-to-treat ( mITT ) and evaluable populations .  
10.2 Efficacy Assessment of ML Subjects  
10.2.1  Assessment Methods  
For subject s with suspected ML, an ENT specialist will examine the nasal and oral mucosa. Each 
of 5 possible sites (nasal skin, nasal mucosa, palate, pharynx, and larynx) will be evaluated for 4 
possible signs of disease (erythema, edema, infiltration, and erosion) and graded on a 0 -3 scale: 0 
= no disease, 1 = mild disease, 2 = moderate disease, 3 = severe disease.  If possible, the ENT 
specialist who first examined the subject  will re -evaluate the or al-nasal mucosa at each follow -up 
visit for the subject  
10.2.2  Clinical Parameter and D efini tion of C linical Responses  
Clinical response will be measured will be a composite score, the mucosal severity score (MSS). 
The MSS is the sum of the severity scores for ea ch clinical sign at each clinical site  of disease . 
The Maximum MSS is 60: grade 3 severity for each of 4 possible signs at each of the 5 possible 
sites.  
 
Healed:   MSS that is 0 in absolute value [equals 0% of the entrance MSS score].  
Improved:   MSS that i s 1% -25% of the entrance MSS score.  
Non-substantial Change:   MSS that is 26% -99% of the entrance MSS score.  
Worse:   MSS >100% of the entrance MSS score.  
Relapse:   MSS substantially increases after initially improving or becoming 0.  
10.2.3  Definition of Subject  Responses  
Subject  cure:   Clinical cure is lesion is healed.  
Subject  failure:   Leasion did not heal. NOTE: The intended response to therapy is a progressive 
diminution in signs and symptoms and no relapse. Subject  failure is  defined as clinically worse at 
the Week 6 visit or thereafter, OR does not improve at the Month 3 or month 7  visits, OR is not 
healed at the Month 13 visit, OR relapses.   
 
Primary endpoint(s) :   The primary endpoints are the clinical cure rates for the mITT and 
evaluable population.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  32 
Version 1, March 6 , 2010  10.3 Withd rawal f rom Protocol for Lack of Efficacy  
The Treating Physician may choose to withdraw the subject from the protocol for lack of 
efficacy and to initiate rescue (alternative) therapy for ML or CL.  
 
For CL, the basis for lack of efficacy will generally be failure of at least one lesion:  lesion has  
worse ned at the end of therapy or thereafter, OR does not Improve at the Week 6 or Month 3 
visit, OR is not healed at the Month 7 visit, OR relapses, or a new lesion.  
 
For ML, the basis for lack of efficacy will generally be failure:  clinically worse (by MSS score) 
at the Week 6 visit of or thereafter, OR does not improve at the Month 3 or Month 6 visit, OR is 
not healed at the Month 13 visit, OR relapses.   
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  33 
Version 1, March 6 , 2010  11 SAFETY/ADVERSE EVENT S 
11.1 Assessment Methods  
11.1.1  Symptoms  
Medic al history:  At screening, during treatment, and during follow up, subjects will be asked 
general questions about their well being and specific questions about gastrointestinal distress 
(nausea, vomiting, diarrhea). If a medically substantial problem is rep orted, it should be reported 
to the Treating Physician immediately.   
11.1.2  Signs  
At screening, a physical exam of the head, eyes, ears, cardiovascular system, lungs, abdomen 
(liver/spleen), extremities, skin, lymphatic system, neuropsychiatric mental status and  
sensory/motor status, musculoskeletal system and general appearance will be performed. Height 
and weight will be recorded. Vital signs (blood pressure, heart rate, temperature) will be 
recorded. During treatment and follow up, a targeted physical exam wil l be performed if 
prompted by the subject  or the subject ’s appearance. Vital signs will be recorded.  
11.1.3  Laboratory Assessments  
Venous blood will be collected during screening for measurement of hematology parameters to 
be reported [white blood cells (WBC), n eutrophil count, hemoglobin, hematocrit, and platelet 
count] and chemistry parameters including glucose, sodium, potassium, creatinine, ALT , and 
bilirubin.  These baseline values will be used to determine if the subject  has a concomitant 
medical condition.  
 
On nominal days 14 and 28, a blood sample will be collected for AST and creatinine only. On 
follow up visits at Month 3, Month 7, and Month 13 , blood will again be collected for ALT  and 
creatinine if on the previous sample the ALT  value was above the upp er limit of normal , or if the 
creatinine clearance was abnormal. Serum creatinine levels will be used to calculate creatinine 
clearance (CrCl) according to the Cockroft -Gault formula as follows:  
 
Males   CrCl (mL/min) =    [140 – age (years) x body weight (k g)]   
      (72) x (serum creatinine [mg/dL])  
 
Females  CrCl (mL/min) =   0.85 x [140 – age (years) x body weight (kg)]  
(72) x (serum creatinine [mg/dL])  
11.1.4  Pregnancy Test  
For females of child -bearing potential, an FDA -cleared serum or urine pregnancy test that  
measures human β -chorionic gonadotropin will be used during screening, at the end of treatment, 
and during follow up.  
11.1.5  Electrocardiogram (ECG)  
An ECG  will be taken during screening  to evaluate if the subject  has a baseline medical 
condition.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  34 
Version 1, March 6 , 2010   
11.2 AE Definition  
An AE is defined as any reaction, side effect, or untoward event that occurs during the course of 
the clinical trial, whether or not the event is considered investigational product -related or 
clinically significant. For this study, AEs will include events  reported by the subject, as well as 
clinically significant abnormal findings on physical examination or laboratory evaluation.   
 
A new illness, symptom, sign , or clinically significant clinical laboratory abnormality  is 
considered an AE. A  worsening of a  pre-existing condition  or abnormality is also considered an 
AE. The appearance of scars at healed lesion sites will not be reported as an AE.  Stable chronic 
conditions which are present prior to clinical trial entry and do not worsen are not considered 
AEs.  
11.3 Severity Definitions  
Subjective AEs will be graded according to the definitions provided below:  
 
Grade 1:    Mild symptoms invoking a minimum degree of discomfort that are easily tolerated.  
 
Grade 2:    Moderate symptoms that result in a reduction in nor mal daily activity, but is not 
totally incapacitating. This may or may not require medical intervention.  
 
Grade 3:    Severe symptoms that may be totally incapacitating or result in marked reduction in 
normal daily activity. Medical intervention is usually required.  
 
Grade 4:    Potentially life -threatening event that requires emergency intervention or 
hospitalization.  
  
Physical examination AEs and laboratory AEs will be graded according to the National Cancer 
Institute ’s CTC  for AEs. For the expected AEs of  vomiting, diarrhea, ALT  elevation, and 
creatinine elevation, the Common Terminology Criteria are:  
 
Analyte  Grade 1  Grade 2  Grade 3  Grade 4  
ALT  elevated  >ULN – 2.5 x ULN  >2.5 – 5.0 x ULN  >5.0 – 20.0 x ULN  >20.0 x ULN  
Creatinine  >ULN - 1.5 x ULN  >1.5 - 3.0 x ULN  >3.0 - 6.0 x ULN  >6.0 x ULN  
Vomiting  1 episode per day  2 to 5 episodes 
per day  6 to 10 episodes per 
day more than 10 
episodes per day  
Diarrhea  increase of 2 to 3 
stools per day  increase of 4 to 6 
stools per day  7 to 9 stools per day  10 or more st ools 
per day  
 
The Common Terminology Criteria for unanticipated AEs will be accessed if needed.  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  35 
Version 1, March 6 , 2010  11.4 Assessment of Causality  
The relatedness of an AE to the investigational product  is the best estimate of the causal 
relationship between the investigational p roduct  and an AE at the time of reporting. Causality 
will be assessed by the Treating Physician and subsequently by the PI.  
 
Definitions are:  
  
Unrelated:    There is no temporal relationship between the event and the administration 
of the investigational  product  or the event is clearly due to the subject’s 
medical condition, other therapies, or accident.  
 
Unlikely:   There is evidence of exposure to the investigational product  but there is 
another more likely cause of the event.  
 
Possibly Related:    There is some temporal relationship between the event and the 
administration of the investigational product  and the event is unlikely to 
be explained by the subject’s medical condition or other therapies.  
 
Probably Related:    The temporal relationship between th e event and the administration of the 
investigational product  is compelling, and the subject’s medical condition 
and other therapies cannot explain the event.  
 
Definitely Related:    The event follows a reasonable temporal sequence from administration of 
the medication or follows a known or suspected response pattern to the 
medication.  
 
The categories of Definitely Related, P robably Related, and Possibly Re lated will be considered 
investigational product related with regards to summary statistics.  
11.5 AE Actions  and Outcomes  
For each AE that is reported, the actions taken with respect to investigational product  can be:  
1. none  
2. permanently discontinued  
 
Also, outcomes will be recorded  as:  
1. resolved  
2. resolved with sequelae  
3. ongoing  
4. required treatment  
5. unknown  
11.6 Monitorin g and Reporting of Adverse Events  
The Treating Physician will monitor subjects for the occurrence of AEs from time the first 
investigational product  is taken  on Day 1 through t he end of follow up at Month 7 for CL  or 
Month 13 for ML. For the period betwee n Study Day 1 and Study Week 6 (2 weeks after the end 
of therapy), all AEs regardless of seriousness or relationship to the investigational product  are to 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  36 
Version 1, March 6 , 2010  be recorded on the CRF.  For the period Week 6 to Month 7 for CL, or Month 13 for ML, only 
AEs requir ing medical attention are to be recorded on the CRF.  
 
Whenever possible, symptoms should be grouped as a single syndrome or diagnosis. The 
Treating Physician should specify the date of onset, maximum severity grade, his/her opinion as 
to association betwee n the AE and the administration of the investigational product  (causality), 
outcomes including corrective therapy given (if applicable). Clinically significant AEs ongoing 
at the last follow up visit will be followed to resolution or stabilized including t he administration 
of any concomitant medications.  
11.7 Serious Adverse Event (SAE)  
Each AE or reaction will be classified by the Treating Physician as serious or non -serious. Based 
on the seriousness of the AE or reaction appropriate reporting procedures will b e followed.  
An SAE is defined as:  
 
 results in death;  
 is life -threatening;  (NOTE: The term "life -threatening" in the definition of "serious" 
refers to an event in which the subject was at risk of death at the time of the event; it does 
not refer to an eve nt which hypothetically might have caused death if it were more 
severe.)  
 requires in patient  hospitalization or prolongation of existing hospitalization;  
 results in persistent or significant disability/incapacity; or  
 is a congenital anomaly/birth defect.  
 
In addition, important medical events that may not result in death, be life -threatening, or require 
hospitalization may be considered a serious adverse drug reaction, when based on appropriate 
medical judgment that may jeopardize the subject and may require  medical or surgical 
intervention to prevent one of the outcomes listed in the above definition. For this protocol, 
becoming pregnant between Study Day 1 and Month 7 is considered to be an SAE.  
11.8 SAE  Reporting Requirements  
The Treating Physician must report  all SAEs to the PI that are possibly, probably, or definitely 
related to study medication within 24 -hours of learning of the SAE  by email, telephone, or fax . 
 
Within a further 3 working days, the SAE CRF, along with any other appropriate supporting 
docume ntation, must be submitted by the Treating Physician to the PI . 
  
The Data Management Center will prepare a na rrative or a MedWatch (FDA Form 3500 A) if the 
SAE meets the criteria for expedited reporting for an SAE.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  37 
Version 1, March 6 , 2010  12  ANALYTICAL PLAN  
12.1 Sample Size  
As the s tudy is not designed to compare the efficacy of the two treatments, there is no formal 
sample size calculation.  
12.2 Analytic al Populations  
mITT Population:   The mITT population includes all subjects who received any administration 
of an investigational produ ct.   
 
Evaluable Population:   The evaluable population will include all subjects who received daily 
doses of investigational product for at least 25 of the total of 28 days, had lesion measurements at 
the Month 7 for CL or the month 13 visit for ML, and wh o did not receive rescue medications to 
treat leishmaniasis at any time during the study.  
 
Efficacy outcomes will be presented separately for subject s with CL and ML.  
 
Safety Population:   The safety population includes all subjects who received any adminis tration 
of investigational product.  
12.3 General A nalytical Procedures  
Descriptive statistics will be used to present study data. Continuous variables will be presented 
as number of observations (n), mean, standard deviation (SD), median, minimum and maximum 
values. Categorical variables will be presented as counts and percentages.  
12.4 Analysis of Baseline Data  
By-subject and summaries of the baseline data will be provided for the mITT, and evaluable 
populations.  
12.5 Analysis of T reatment Compliance D ata 
By subject a nd summaries of compliance with scheduled treatments will be provided,  including 
total exposure (number of days and total dose) to investigational product .  
12.6 Analysis of Efficacy O utcomes  of CL Subjects  
12.6.1  Lesion Area Measurements  
Summary statistics for each s ubject will include lesion area and change from baseline at each 
measurement time point.  
12.6.2  Lesion and Subject  Cure Rate  
For each subject , the proportion of lesions at each measurement time point that have healed , 
improve d, did not  change , worsen ed, or relaps ed will be calculated. Also for each subject, the 
proportion of all lesions that cured and all lesions that failed will be presented. The proportion of 
subject s who cure or fail will be calculated. This data will be presented for the mITT and 
evaluable pop ulations.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  38 
Version 1, March 6 , 2010   
12.6.3  Handling of Missing Data  
Missing lesion measurements will be ignored when presented as summary statistics of lesion 
areas  and lesion responses as presented by numbers of lesions evaluated at each time point . 
Subjects who do not provide lesion re sponse measurements at their final scheduled follow up 
will be considered lesion ane subject failures in the mITT analysis.  
 
Note that if a subject  does not appear at the scheduled Study Week 6, Month 3, or Month 7 visits, 
the subject ’s estimate of his/her  lesion response may be obtained from the subject  by telephone, 
and will be noted as obtained in that manner. Such data is not defined as missing. For such data, 
the Treating Physician and the PI will jointly decide if the subject ’s estimate is likely to b e 
reliable. In a single -group non -comparative study such as this one, errors in interpretation will 
only apply to miltefosine subject s and will not be corrected by being equally applied to a 
comparator group. Therefore, it is important for subject , physici an, and Investigator to avoid two 
potential errors:  1) erroneously viewing a lesion as healed when in fact it is still present, 2) 
erroneously viewing a lesion as failed because a subject  does not show up for clinic, when in fact 
the lesion has healed and  the subject  does not want to spend time coming to clinic.  
12.7 Analysis of Efficacy Outcomes  of ML S ubjects  
12.7.1  Lesion assessments  
Summary statistics for each subject will include the individual components of the MSS score and 
the total MSS score, and change from baseline in both parameters, at each measurement time 
point.  
12.7.2  Subject  Cure Rate  
The proportion of subject s at each measurement time point with clinical cure, improvement , fail, 
and relapse will be calculated.  Data will be presented for the mITT and evaluab le populations.  
12.7.3  Handling of Missing Data  
Missing lesion measurements will be ignored when presented as summary statistics of lesion 
areas  and lesion responses as presented by numbers of lesions evaluated at each time point . 
Subjects who do not provide lesi on measurements at their final scheduled follow up will be 
considered clinical failures in the mITT analysis.  
 
Note that because the subject  cannot accurately examine his/her oro -nasal membranes, subject  
reports of physical mucosal examination cannot be ac cepted.  
12.8 Analysis of Safety Data  
Symptoms (subjective AEs) will be coded using the most recent version of the Medical 
Dictionary of Regulatory Affairs (MedDRA) by assigning a preferred term and will be grouped 
by system, organ, and class (SOC) designation. Listings of each individual AE including start 
date, stop date, severity, relationship, duration, and outcome will be provided.  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  39 
Version 1, March 6 , 2010  Laboratory data and physical signs (including vital signs) will be presented as summary statistics 
by Study Day including chan ges from baseline as well as in by -subject data listings. A summary 
and listing of analyte concentrations and vital signs for subjects with levels outside normal 
laboratory limits will also be presented.  Clinically significant AEs , SAEs, discontinuation du e to 
AEs, and other significant AEs  will be individually listed and narrated.  
 
The above safety analysis will be provided for the mITT and Evaluable populations.  
13  ADMINISTRATIVE AND R EGULATORY STANDARDS  
An IND will be obtained from the FDA. The PI will si gn a Form FDA 1572.  
13.1 Ethical R eview of Protocol    
The PI will obtain protocol approval fr om a central IRB before starting the study.  
13.2 Informed Consent  
Each subject ’s Treating Physician will be responsible for obtaining informed consent from that 
subject  prior to his/her participation. If that subject ’s treatment will occur in a facility over which 
an IRB has responsibility and that IRB requires review of the protocol, the Treating Physician 
will obtain approval from that IRB prior to the subject ’s participa tion in the protocol.  
13.3 Responsibility for Subject  Care 
The Treating Physician is responsible for the care of his/her subject .  
13.4 Treatment Cost  
Miltefosine will be provided by the Sponsor at no cost; however, subject  care is the 
responsibility of the Treating  Physician and no payment for subject  care can be made by the 
Sponsor.  
13.5 Protocol Exemption Committee  
The PI and the Sponsor’s Representative will constitute the protocol exemption committee.  
14  STUDY DOCUMENTATION/ DATA MANAGEMENT  
The data management plan and  a statistical analysis plan will be prepared by the data 
management center . 
14.1 Subject Identification (ID) Code   
Each subject will be assigned a subject ID code which will be provided with the screening CRF 
package . The subject ID  code will consist  of a thre e digit numeric code and a three digit 
alphabetical (alpha) code. The first digit of the numeric code will be a sequential number starting 
with 101. The alpha code will be a random sequence of three letters. The Subject ID code will be 
used on all CRFs, an d laboratory data sheets .  
14.2 Data Collection and M onitoring  
Data will be collected at the study site in the subject ’s medical records, which will be transcribed 
at the site  on to the study CRFs  provided by the data management center . CRFs are to be 
completed  on an ongoing basis according to the instructions in the Study Procedures Manual.  
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  40 
Version 1, March 6 , 2010   
The Treating Physician will be responsible for completing the CRFs , verifying the accuracy of 
the CRF data versus the source documentation , and sen ding the completed CRFs to the d ata 
management  center.  
 
The Treating Physician will correspond with the PI at the following time points:  
 
 prior to obtaining informed consent to verify subject  eligibility , 
 Study Day 28 or Week 6 follow -up visit,  
 Month 7 follow up for CL subjects,  or Month 7 and 13 for ML subject s. 
 
Completed CRF s should be submitted to the data management center prior to the Treati ng 
Physician contacting the PI  by telephone. The purpose of these communications between 
Treating Physician and P I is to assure optimum  subject  care and conveyance of study data.  
 
The Treating Physician and PI  can also correspond with each other at any other time of their 
choosing.  
 
In spite of these interactions and advice that may be offered by the P I, clinical responsibility for 
subje ct care rests with the Treating Physician.  
14.3 Data Editing and Control  
Data received at Fast -Track will be reviewed prior to being entered into the main study database. 
If incomplete or inaccurate data are found, a data clarification request will be forwarded  to the 
clinical site for a response. The site will resolve data inconsistencies and errors prior to returning 
data to Fast -Track. Errors must be corrected by drawing a single line through the incorrect entry 
and by writing the new value as close to the or iginal as possible. The correction must then be 
initialed and dated. All corrections and changes to the data will be reviewed prior to being 
entered into the main study database  
14.4 Data Analysis  
A final analysis of all clinical trial data will be performed wh en all of the data for ev ery subject 
has been collected, entered into the main study database, audited, and locked for analysis. A final 
clinical study report will be prepared in accordance with International Committee  on 
Harmonization E3 Structure and Con tent of Final Clinical Study Reports.  
14.5 Publication  
The results of the full study may be published at the discretion of the sponsor. The Treating 
Physician may publish or  present the data of his/her patients provided that the 
publication/presentation does n ot disclose any of the Sponsor’s Proprietary  Information.  The 
Treating Physician  agrees to submit the draft of any proposed publication/presentation to 
Sponsor at least thirty (30) days prior to submission for publication/ presentation, and agrees, at 
the request of Sponsor , to withhold any such submission for an additional period, not to exceed 
ninety (90) days, to allow Sponsor to file patent applications or to take any other action designed 
to protect its patent rights. No personal data will be used in any external communication or 
publication . 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  41 
Version 1, March 6 , 2010  14.6 Subject Confidentiality  
To maintain subject confidentiality, all records and CRFs specifically generated by this protocol 
will be identified using the subject ID code.  Protocol  generated records will be stored in a secure 
location and only the protocol staff will have access to the records.  
15 ROLES AND RESPONSIBI LITIES OF STUDY PERS ONNEL  
15.1 Principal Investigator   
Signs the protocol agreement, below, and the Form FDA 1572.  The PI is responsible for passage 
of the prot ocol and any amendments through a “central” I RB before starting the study. The PI is 
responsible for interaction with Treatment Physicians to ensure protocol adherence and data 
integrity , and overall coordination of the study.  
 
The PI is also responsible for participating in safety evaluations of subjects du ring the conduct of 
the study. The PI will review all unanticipated problems involving risk to subjects or to others, 
SAEs, and all subjects’ deaths associated with the protocol , and provide an unbiase d written 
report of the event. At a minimum, the PI should comment on the outcomes of the event or 
problem and, in the case of a SAE or death, comment on the relationship to participation in the 
study. The PI should also indicate whether he/she concurs with  the details of the report provided 
by the Treating Physician. Reports for SAEs determined by either the Treating Physician or PI to 
be possibly, probably, or definitely related to participation and reports of events resulting in 
death should be promptly f orwarded to the Sponsor and the “central” IRB.  
  
The PI is responsible for filing a final clinical study report with the Sponsor.  
15.2 Associate Investigator  
Associate investigators are responsible for performing the PI’s duties in his/her absence.  In all 
sections of this protocol, “PI” is taken to mean “PI or Associate PI in the absence of the PI”.  
15.3 Treating Physicians  
This protocol inv olves the clinical use of an investigational agent . Treating Physicians are 
responsible for implementation of protocol with res pect to his/her subject : briefing potential 
participants, obtaining prop er informed consent, obtaining IRB approval if needed, determining 
study eligibility based on inclusion and exclusion criteria, accountability and proper storage of 
the investigational  product,  administering the product to the patients,  reporting of any AEs or 
protocol deviations,  entering and verifying CRF data, reporting study data to the Data 
Management Center via CRFs, and corresponding with the PI at scheduled time periods.  
 
  
The Treating Physician is considered an “investigator” in the regulatory sense , and has to supply 
a Form FDA 1572 and curriculum vitae to the PI so that these documents can be sent to the FDA .  
 
Protocol No.PLB -MILT -201:  Treatment of Mucocutaneous Leishmaniasis with Miltefosine  42 
Version 1, March 6 , 2010  15.4 Data Management Center   
Prepare and provide CRFs to clinical sit e; design, develop, and validate the clinical trial 
database; perform data entry into the clinical trial database; perform database quality control and 
data analysis.  
16 STATEMENT OF AGREEME NT 
The PI has carefully read this protocol and agrees to oversee the clinical study as described in a 
professional and competent manner in accordance with the generally accepted standards of Good 
Clinical Practice.  
 
The Treating Physician has carefully read this protocol and agrees to oversee the clinical 
treatment as desc ribed in a professional and competent manner in accordance with the policies of 
the medical institution where the Treating Physician conducts the clinical treatment and any 
applicable local, state, and agency laws and regulations. The Treating Physician un derstands that 
the IND has been submitted the protocol to FDA. The Treating Physician agrees to cooperate 
with and be available to regulatory authorities as needed regarding the conduct of this clinical 
study.  
 
The Treating Physician further attests that h e/she has obtained informed consent from the subject  
to be treated under this protocol.  
17 SIGNATURE S 
 
      
____________________________ ____   _______________________  
Principal Investigator      Date  
Jonathan Berman, M.D., Ph.D.  
 
 
_____________________________ ___  _______________________  
Sponsor       Date  
Robert K. Vinson, Ph.D.       
 
 
________________________________   _______________________  
Treating Physician      Date  
Name:   
 
 